Generics will continue to dominate Central and Eastern European pharma markets until 2011
The pharmaceutical market in Central and Eastern Europe is dominated by generic drugs, with this subdivision worth 17.2 billion euros ($25.5 billion) in 2008 and expected to develop by around 14% per annum between 2009 and 2011, according to the Poland-based market research and consultancy group PMR.
The growth rate of the innovative drug market, which was worth 12.4 billion euros in 2008, will be slower, says a report from PMR, entitled Generic and innovative drugs market in Central and Eastern Europe 2009. Comparative analysis, reimbursement policies and development forecasts for 2009-2011.
Generics to account for nearly 60% of the market in 2009
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze